atalyst is a biopharmaceutical company focused on the development and commercialization of prescription drugs to fight addictions, manage pain, and treat diseases of the central nervous system such as epilepsy.
Catalyst is developing vigabatrin (vi•gá•ba•trin, designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine, and other addictive substances. Catalyst is also developing a more potent form of vigabatrin (designated CPP-115 by Catalyst) to combat drug addiction — including opiate addiction in managing pain — and to treat central nervous system indications such as epilepsy.
The FDA has designated Catalyst’s CPP-115 as a Fast Track Development Program for treating cocaine dependency. More »
Catalyst starts Phase I(a) human safety study for CPP-115. More »
CPP-109 and CPP-115 are Catalyst's two product candidates for treating addictions and epilepsy. More »
Catalyst has obtained exclusive worldwide licenses from Brookhaven National Laboratory and Northwestern University to commercialize CPP-109 and CPP-115. More »
Site Map Contact Us Copyright 2010–2012 Catalyst Pharmaceutical Partners
